FAILED
首站-论文投稿智能助手
典型文献
Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics
文献摘要:
Gefitinib has been available in the market for 20 years,but its pharmacokinetic mechanism of response is little known.In this study,we examined the pharmacokinetic and metabolomic profiles in non-small cell lung cancer(NSCLC)patients with sensitive EGFR mutations.A total of 216 advanced NSCLC patients were enrolled,and administered gefitinib at the standard dosage of 250 mg/day,which was established in heterogeneous subjects with non-sensitive mutations.We identified and quantified three main metabolites(named as M1,M2 and M3)in the plasma of patients,the correlations between the concentration of gefitinib/metabolites and efficacy were analyzed.In exploratory and validation set,gefitinib concentration was not correlated with clinical effects.Considering the result that the therapeutic effects of 250 mg/2-day was better than that of 250 mg/day in a multiple center clinical trial,the standard dose might be higher than that for maximal efficacy according to the hypothetical dose-response curve.Among the three metabolites,the IC50 of M2 in HCC827 and PC9 cell lines was significantly lower,and Conc.brain/Conc.plasma of M2 in mice was significantly higher than those of gefitinib,suggesting its higher potential to penetrate blood-brain barrier and might be more effective in the treatment of brain metastatic tumor than gefitinib.Consistently and attractively,higher M2 plasma concentration was found to be correlated with better clinical outcome in patients with brain metastases(the median PFS of CM2<12 ng/mL and CM2≥12 ng/mL were 17.0 and 27.1 months,respectively,P = 0.038).The plasma concentration of M2≥12 ng/mL was a strong predictor of the PFS of NSCLC patients.In conclusion,for NSCLC patients with EGFR sensitive mutations,the standard dose is suspectable and could be decreased reasonably.M2 plays an important role in efficacy and may be more effective in the treatment of metastatic tumor than gefitinib.
文献关键词:
作者姓名:
Wei Feng;Xi Chen;Shao-xing Guan;Hong-lian Ruan;Yan Huang;Hui-zhen Zhang;Yun-peng Yang;Wen-feng Fang;Hong-yun Zhao;Wei Zhuang;Shuang Xin;You-hao Chen;Fei Wang;Yue Gao;Min Huang;Xue-ding Wang;Li Zhang
作者机构:
Institute of Clinical Pharmacology,School of Pharmaceutical Sciences,Sun Yat-Sen University,Guangzhou 510006,China;Department of Medical Oncology,Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in South China,Guangzhou 510060,China;School of Public Health,Guangzhou Medical University,Guangzhou 510000,China;Ersha Department of Pharmacy,The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510120,China
引用格式:
[1]Wei Feng;Xi Chen;Shao-xing Guan;Hong-lian Ruan;Yan Huang;Hui-zhen Zhang;Yun-peng Yang;Wen-feng Fang;Hong-yun Zhao;Wei Zhuang;Shuang Xin;You-hao Chen;Fei Wang;Yue Gao;Min Huang;Xue-ding Wang;Li Zhang-.Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics)[J].中国药理学报(英文版),2022(07):1857-1864
A类:
Conc,attractively,suspectable
B类:
Rational,application,gefitinib,NSCLC,patients,sensitive,EGFR,mutations,pharmacokinetics,metabolomics,Gefitinib,has,been,available,market,years,but,its,mechanism,response,little,known,In,this,study,examined,profiles,small,cell,lung,cancer,total,advanced,were,enrolled,administered,standard,dosage,day,which,was,established,heterogeneous,subjects,We,identified,quantified,three,main,metabolites,named,M1,M3,plasma,correlations,between,concentration,efficacy,analyzed,exploratory,validation,set,not,correlated,clinical,effects,Considering,result,that,therapeutic,better,than,multiple,center,trial,dose,might,higher,maximal,according,hypothetical,curve,Among,IC50,HCC827,PC9,lines,significantly,lower,brain,mice,those,suggesting,potential,penetrate,blood,barrier,more,effective,treatment,metastatic,tumor,Consistently,found,outcome,metastases,median,PFS,CM2,months,respectively,strong,predictor,conclusion,could,decreased,reasonably,plays,important,role,may
AB值:
0.456664
相似文献
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
Yujiao Wang;Xi Jiao;Shuang Li;Huan Chen;Xin Wei;Chang Liu;Jifang Gong;Xiaotian Zhang;Xicheng Wang;Zhi Peng;Changsong Qi;Zhenghang Wang;Yanni Wang;Na Zhuo;Jianling Zou;Henghui Zhang;Jian Li;Lin Shen;Zhihao Lu-Department of Gastrointestinal Oncology,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Gastric&Colorectal Surgery,The First Hospital of Jilin University,Changchun 130021,China;Genecast Precision Medicine Technology Institute,Beijing 100192,China;Life Sciences Institute,Zhejiang University,Hangzhou 310058,China;Institute of Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China
Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis
Haoran Mu;Dongqing Zuo;Jie Chen;Zhigang Liu;Zhuo Wang;Liu Yang;Qihui Shi;Yingqi Hua-Shanghai Bone Tumor Institute and Department of Orthopedics,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China;Key Laboratory of Systems Biomedicine(Ministry of Education),Shanghai Center for Systems Biomedicine,Shanghai Jiao Tong University,Shanghai 200240,China;Shanghai Key Laboratory of Medical Epigenetics and the International Co-laboratory of Medical Epigenetics and Metabolism(MOST),Institutes of Biomedical Sciences,Fudan University,Shanghai 200032,China;Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer(SMHC)and Institute of Fudan-Minhang Academic Health System,Minhang Hospital,Fudan University,Shanghai 201199,China;Shanghai Engineering Research Center of Biomedical Analysis Reagents,Shanghai 201203,China
Enzyme-linked immunosorbent assays for quantification of MMMAE-conjugated ADCs and total antibodies in cynomolgus monkey sera
Min Pei;Tingting Liu;Lu Ouyang;Jianhua Sun;Xiaojie Deng;Xiaomin Sun;Wei Wu;Peng Huang;Yi-Li Chen;Xiaorong Tan;Xiaoyue Liu;Peng Zhu;Yongzhen Liu;Deheng Wang;Junliang Wu;Qi Wang;Guifeng Wang;Likun Gong;Qiuping Qin;Chunhe Wang-Biotherapeutics Discovery Research Center,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,201203,China;School of Pharmacy,University of Chinese Academy of Sciences,Beijing,100049,China;Center for Drug Safety Evaluation and Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,201203,China;Research and Development Center,Dartsbio Pharmaceuticals Ltd.,Zhongshan,Guangdong,528400,China;Zhongshan Institute for Drug Discovery,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Zhongshan,Guangdong,528400,China;School of Pharmacy,Shanghai Engineering Research Center of Immunotherapeutics,Fudan University,Shanghai,201203,China
A trial of arbidol hydrochloride in adults with COVID-19
Zhao Jingya;Zhang Jinnong;Jin Yang;Tang Zhouping;Hu Ke;Sun Hui;Shi Mengmeng;Yang Qingyuan;Gu Peiyu;Guo Hongrong;Li Qi;Zhang Haiying;Li Chenghong;Yang Ming;Xiong Nian;Dong Xuan;Xu Juanjuan;Lin Fan;Wang Tao;Yang Chao;Huang Bo;Zhang Jingyi;Chen Shi;He Qiong;Zhou Min;Qu Jieming-Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Department of Emergency, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory and Critical Care Medicine, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Respiratory and Critical Care Medicine, Renmin Hospital, Wuhan University, Wuhan, Hubei 430060, China;Department of Endocrinology, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory Medicine, Wuhan Bauhinia Hospital, Wuhan, Hubei 430062, China;Department of Respiratory Medicine, Guanggu Hospital District, The Third Hospital of Wuhan, Wuhan, Hubei 430074, China;Department of Respiratory and Critical Care Medicine, Puren Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430081, China;Department of Respiratory Medicine, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China;Department of Respiratory Medicine, The Sixth General Hospital of Hubei Province, Wuhan, Hubei 430015, China;Tuberculosis Department of Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan 610066, China;Department of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei 430015, China;Department of Tuberculosis, Jinyintan Hospital, Wuhan, Hubei 430048, China;Department of Cardiology, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China
Efficacy and safety of high-dose esomeprazole–amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial
Bi Hanxin;Chen Xingxing;Chen Yuxin;Zhao Xin;Wang Shasha;Wang Jiehong;Lyu Ting;Han Shuang;Lin Tao;Li Mingquan;Yuan Donghong;Liu Junye;Shi Yongquan-Xi’an Medical University, Xi’an, Shaanxi 710021, China;State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi 710032, China;Department of Gastroenterology, Xianyang Central Hospital, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Shaanxi Nuclear Industry 215 Hospital, Xianyang, Shaanxi 712000, China;Department of Gastroenterology, Xi’an Red Cross Hospital, Xi’an, Shaanxi 710054, China;Department of Gastroenterology, Xi’an Daxing Hospital, Xi’an, Shaanxi 710082, China;Department of Gastroenterology, Yan’an People’s Hospital, Yan’an, Shaanxi 716000, China;Department of Gastroenterology, Yan’an University Affiliated Hospital, Yan’an, Shaanxi 716000, China;Department of Radiation Protective Medicine, Air Force Medical University, Xi’an, Shaanxi 710032, China
Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity
Liu Zuojing;Zhu Shiwei;He Meibo;Li Mo;Wei Hui;Zhang Lu;Sun Qinghua;Jia Qiong;Hu Nan;Fang Yuan;Song Lijin;Zhou Chen;Tao Heqing;Y Kao John;Zhu Huaiqiu;Owyang Chung;Duan Liping-Department of Gastroenterology, Peking University Third Hospital, Haidian District, Beijing 100191, China;Department of Ultrasound, Peking University Third Hospital, Haidian District, Beijing 100191, China;Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China;Department of Biomedical Engineering, College of Engineering, Peking University, Beijing 100187, China;Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, 6520 MSRB I, SPC 5682, 1150 West Medical Center Drive, Ann Arbor, MI 48109, USA
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1
Li Mingzhe;Zhou Jiaxin;Zhang Zhengkui;Li Jisong;Wang Feng;Ma Ling;Tian Xiaodong;Mao Zebin;Yang Yinmo-Department of General Surgery, Peking University First Hospital, Beijing 100034, China;Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, China;Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China;Department of Surgical Oncology, Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing 100038, China;Department of Medical Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China
Hepatopancreatoduodenectomy for advanced biliary malignancies
Wu Xiangsong;Li Maolan;Wu Wenguang;Wang Xu’an;Li Huaifeng;Bao Runfa;Shu Yijun;Shen Jun;Gu Jun;Wang Xuefeng;Gong Wei;Peng Shuyou;Liu Yingbin-Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai 200092, China;Shanghai Research Center of Biliary Tract Disease, Shanghai 200092, China;Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;State Key Laboratory of Oncogenes and Related Genes, Shanghai 200092, China;Department of General Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejing 310009, China
FOX03 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
Shaoxing Guan;Xi Chen;Youhao Chen;Guohui Wan;Qibiao Su;Heng Liang;Yunpeng Yang;Wenfeng Fang;Yan Huang;Hongyun Zhao;Wei Zhuang;Shu Liu;Fei Wang;Wei Feng;Xiaoxu Zhang;Min Huang;Xueding Wang;Li Zhang-Laboratory of Drug Metabolism and Pharmacokinetics,School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510060,China;State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;College of Health Science,Guangdong Pharmaceutical University,Guangzhou 510006,China;Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510080,China;Ersha Department of Pharmacy,the Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510105,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。